Abstract
The concept of theranostics, where individual patient-level biological information is used to choose the optimal therapy for that individual, has become more popular in the modern era of ‘personalised’ medicine. With the growth of theranostics, nuclear medicine as a specialty is uniquely poised to grow along with the ever-increasing number of concepts combining imaging and therapy. This special report summarises the status and growth of Theranostic Nuclear Medicine in Singapore. We will cover our experience with the use of radioiodine, radioiodinated metaiodobenzylguanidine, peptide receptor radionuclide therapy, prostate specific membrane antigen radioligand therapy, radium-223 and yttrium-90 selective internal radiation therapy. We also include a section on our radiopharmacy laboratory, crucial to our implementation of theranostic principles. Radionuclide theranostics has seen tremendous growth and we hope to be able to grow alongside to continue to serve the patients in Singapore and in the region.
Similar content being viewed by others
References
Verburg FA, Heinzel A, Hänscheid H, Mottaghy FM, Luster M, Giovanella L. Nothing new under the nuclear sun: towards 80 years of theranostics in nuclear medicine. Eur J Nucl Med Mol Imaging. 2014;41(2):199–201. https://doi.org/10.1007/s00259-013-2609-2.
Taieb D, Hicks RJ, Pacak K. Nuclear medicine in cancer theranostics: beyond the target. J Nucl Med. 2016;57(11):1659–60. https://doi.org/10.2967/jnumed.116.178343.
Parmeswaran R. Multidisciplinary care for well differentiated thyroid cancer. 2016. http://emss.org.sg/wp-content/uploads/2017/10/Thyroid-Cancer-Consensus-SG-Quick-Reference-Guide.pdf. Accessed 26 December 2018.
Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors. Pancreas. 2010;39(6):707–12. https://doi.org/10.1097/MPA.0b013e3181ec124e.
Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177 Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35. https://doi.org/10.1056/NEJMoa1607427.
Sadowski SM, Neychev V, Millo C, et al. Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol. 2016;34(6):588–96.
Zaknun JJ, Bodei L, Mueller-Brand J, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800–16. https://doi.org/10.1007/s00259-012-2330-6.
Kwekkeboom DJ, Krenning EP, Lebtahi R, et al. ENETS consensus guidelines for the standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009;90(2):220–6. https://doi.org/10.1159/000225951.
Thang SP, Lung MS, Kong G, et al. Peptide receptor radionuclide therapy (PRRT) in European neuroendocrine tumour society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. Eur J Nucl Med Mol Imaging. 2017 Nov;20.
Kao YH, Hock Tan AE, Burgmans MC, et al. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modelling for safe and effective 90Y radioembolization. J Nucl Med. 2012;53(4):559–66.
Kao YH, Steinberg JD, Tay YS, et al. Post-radioembolization yttrium-90 PET/CT – part 1: diagnostic reporting. EJNMMI Res. 2013;3(1):56.
Kao YH, Steinberg JD, Tay YS, et al. Post-radioembolization yttrium-90 PET/CT – part 2: dose-response and tumor predictive dosimetry for resin microspheres. EJNMMI Res. 2013;3(1):57.
Yan SX, Lim GK. Optimizing reconstruction algorithm to improve quality of post-PRRT Yittrium-90 PET scan. Neuroendocrinology. 2018;106(suppl 1):1–301.
Rodriguez LS, Thang SP, Li H, et al. A descriptive analysis of remnant activity during (90)Y resin microspheres radioembolization of hepatic tumors: technical factors and dosimetric implications. Ann Nucl Med. 2016;30(3):255–61.
Tong AK, Kao YH, Too CW, et al. Yttrium-90 hepatic radioembolization: clinical review and current techniques in inteventional radiology and personalized dosimetry. Br J Radiol. 2016;89(1062):20150943.
NCC website: https://www.nccs.com.sg. Accessed 26 December 2018.
Lam WWC, Goh C, Chua MLK, Tan J. 270P 68Ga prostate-specific membrane antigen positron emission tomography for evaluation of biochemical recurrence of prostate cancer - our local experience. Ann Oncol. 2017;28(suppl_10). https://doi.org/10.1093/annonc/mdx662.009.
Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71(2):151–4.
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54.
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–60.
Ahmadzadehfar H, Rahbar K, Kurpig S, et al. Early side effects and first results of radioligand treatment with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5:114.
Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85–90.
Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016;57:1170–6.
Yadav MP, Ballal S, Tripathi M, et al. 177Lu-DKFZ-PSMA-617 treatment in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging. 2017;44:81–91.
Heck MM, Retz M, D‘Alessandria C, et al. Systemic radioligand therapy with (177)Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer. J Urol. 2016;196:382–91.
Kulkarni HR, Singh A, Schuchardt C, et al. PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the bad Berka experience since 2013. J Nucl Med. 2016;57(suppl 3):97S–104S.
Baum RP, Kulkarni HR, Schuchardt C, et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57:1006–13.
Fendler WP, Reinhardt S, Ilhan H, et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer. Oncotarget. 2017;8:3581–90.
Hofman MS, Violet J, Hicks RJ, et al. 177Lu-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825–33.
Yordanova A, Linden P, Hauser S, Meisenheimer M, Kürpig S, Feldmann G, et al. Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2018. https://doi.org/10.1007/s00259-018-4222-x.
Heck MM, Tauber R, Schwaiger S, Retz M, D'Alessandria C, Maurer T, et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol. 2018. https://doi.org/10.1016/j.eururo.2018.11.016.
Acknowledgements
We wish to acknowledge the invaluable contributions of our radiopharmaceutical laboratory staff, nurses, nuclear medicine technologists and managers, without whom, none of our nuclear theranostic efforts will be possible.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Hian Liang Huang, Aaron Kian Ti Tong, Sue Ping Thang, Sean Xuexian Yan, Winnie Wing Chuen Lam, Kelvin Siu Hoong Loke, Charlene Yu Lin Tang, Lenith Tai Jit Cheng, Gideon Su Kai Ooi, Han Chung Low, Butch Maulion Magsombol, Wei Ying Tham, Charles Xian Yang Goh, Colin Jingxian Tan, Yiu Ming Khor, Sumbul Zaheer, Pushan Bharadwaj, Wanying Xie and David Chee Eng Ng declare no conflict of interest.
Ethical Statement
Ethical approval is not required for this work.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Huang, H.L., Tong, A.K.T., Thang, S.P. et al. Current Status and Growth of Nuclear Theranostics in Singapore. Nucl Med Mol Imaging 53, 96–101 (2019). https://doi.org/10.1007/s13139-019-00580-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13139-019-00580-3